Date:11/9/2010

ociated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:Kelly Lindenboom

Vice President, Corporate Communications

617-674-5335

kelly.lindenboom@verenium.comSarah Carmody

Manager, Corporate Communications

617-674-5357

sarah.carmody@verenium.comVerenium CorporationConsolidated Statements of Operations(unaudited, in thousands, except per share amounts)Three Months Ended
September 30, Nine Months Ended
September 30, 201020092010
'/>"/>

SOURCE Verenium Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Verenium to Present at Jefferies 10th Global Clean Technology Conference
2. Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement
3. Verenium Announces Regulatory Approval for Purifine® PLC in China
4. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
5. Verenium Appoints Kevin Bracken Vice President of Manufacturing
6. Verenium Announces Proposed Public Offering of Common Stock
7. Verenium 1:12 Reverse Stock Split Takes Effect
8. Verenium Announces Reverse Stock Split to Take Effect September 9
9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
10. Verenium Completes Amendment to 8% Senior Convertible Notes
11. Verenium Announces Organizational Changes